The Lactococcus lactis strain Plasma anti-viral immune system
Lactic acid bacteria have been receiving increased attention amid reports of insufficient supplies of the influenza vaccine. However, the characteristics of the different lactic acid bacteria are not widely known. In this article, we will describe the features of Lactococcus lactis strain Plasma (Lactococcus Plasma), an original Kirin product, as well as its recently uncovered anti-viral immune system.
1. What is Lactococcus Plasma?
Plasmacytoid dendritic cells (pDCs): the “commander in chief” of the immune system
pDCs are one ofvarious types of immune cells. The defining characteristics of pDCs are that they respond to and are triggered into activation by viruses and that they produce interferon alpha (IFN-α). IFN-α transmits signals to other immune cells to, for example, suppress viral/cancer cells or suppress cell proliferation. That is, pDCs play the “commander in chief” of the immune system, activating other immune cells. Conventional lactic acid bacteria can activate some types of immune cells, such as natural killer (NK) cells. However, they are unable to activate the pDCs which in turn activate a variety of other immune cells; it was held impossible worldwide for any lactic acid bacterium to activate pDCs.
Lactococcus Plasma discovered by Kirin
The established theory was that no lactic acid bacteria able to activate pDCs existed. However, we took up the challenge to overturn this theory by identifying a strain of such lactic acid bacteria and converting it into an effective technology to reduce the risk of viral infection. After exploring over 100 lactic acid bacteria using cutting-edge technology, in 2010 Kirin succeeded in discovering a lactic acid bacterium that activates plasmacytoid dendritic cells, and named it Lactococcus Plasma.
A pDC before the addition of Lactococcus Plasma
A pDC after the addition of Lactococcus Plasma
2. New research findings
We have continued our research into Lactococcus Plasma since its discovery; various experiments have proved its highly effective anti-viral defense mechanism. Wider applications for Lactococcus Plasma can be expected as its mechanism is further explored. The research results have been published and extensively evaluated, attracting a great deal of attention among academic societies, etc. We would like to outline some of the recent research results into the Lactococcus Plasma anti-viral immune system, as follows.
Finding 1. Increase in Immunoglobulin A (IgA)
IgA plays a crucial role in the immune mechanism of the digestive and respiratory tracts. It is also a component of colostrum for the protection of newborns against bacteria and viruses. Its characteristics include the capacity to respond to various types of pathogens and its presence in mucosal membranes (e.g. saliva, the nasal cavity), entry points for foreign bodies. As a result of analyzing the amount of IgA in saliva, it was found that those who had taken Lactococcus Plasma (the Lactococcus Plasma group) had a higher amount of IgA compared to those who had not (the placebo group).
Finding 2. Maintaining the level of expression of virus resistance genes in those who had taken the vaccine
Those who had also received the influenza vaccine maintained their levels of the influenza virus resistance gene to a significantly higher extent, indicating the possibility of an additive effect between Lactococcus Plasma intake and the influenza vaccination.
Through uncovering the above mechanism, we have identified that Lactococcus Plasma not only contributes to the prevention of a range of viral infections but is also expected to have an additive effect in those who have received the influenza vaccination.
Kirin will continue to undertake research into Lactococcus Plasma as part of its ongoing contribution to consumer well-being.